

MEF2D Antibody

Rabbit Polyclonal

Antigen Affinity Purified

Protein ID NP_005911.1

Catalog No. A303-521A


GeneID 4209

Lot No. A303-521A-1




APPLICATIONS	WB, IP, IHC
SPECIES REACTIVITY	Human
AMOUNT	100 µl
CONCENTRATION	200 µg/ml
STORAGE/SHELF LIFE	2 - 8° C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
ISOTYPE	IgG
ORIGIN	USA
PRODUCTION PROCEDURES	<p>Antibody was affinity purified using an epitope specific to MEF2D immobilized on solid support.</p> <p>The epitope recognized by A303-521A maps to a region between residue 425 and 475 of human Myocyte Enhancer Factor 2D using the numbering given in entry NP_005911.1 (GeneID 4209).</p> <p>Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.</p>
APPLICATIONS	<p>Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.</p> <p>Western Blot 1:2,000 – 1:10,000</p> <p>Immunoprecipitation 2 – 10 µg/mg lysate</p> <p>Immunohistochemistry 1:100 – 1:500. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.</p>
APPLICATION NOTES	<p>Western blot of immunoprecipitates performed using Normal Pig Serum (Cat. No. S100-020), Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120-113P) and 4-20% SDS-PAGE (link to IP-western blot protocol in Additional Info section below).</p> <p>Western blot of lysates performed using standard western blot reagents and 4-20% SDS-PAGE.</p>
IHC HUMAN CONTROLS	Breast Carcinoma, Prostate Carcinoma, Stomach Adenocarcinoma
ADDITIONAL INFO	<p>https://www.bethyl.com/product/A303-521A</p> <p>Use the link above to view SDS, a current list of citations, and other product specific information.</p> <p>IP-western blot protocol: https://www.bethyl.com/content/protocol_IP_WB</p>

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Eric McIntush, PhD | Chief Scientific Officer Date: June 21, 2019



Detection of human MEF2D by western blot and immunoprecipitation. *Samples:* Whole cell lysate from HeLa (15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 µg) and Jurkat (J; 50 µg) cells. *Antibodies:* Affinity purified rabbit anti-MEF2D antibody A303-521A used for WB at 0.04 µg/ml (A) and 1 µg/ml (B) and used for IP at 6 µg/mg lysate. MEF2D was also immunoprecipitated by rabbit anti-MEF2D antibody A303-522A, which recognizes a downstream epitope. *Detection:* Chemiluminescence with exposure times of 3 minutes (A) and 10 seconds (B).



Detection of human MEF2D by immunohistochemistry. *Samples:* FFPE serial sections of human breast carcinoma. *Antibody:* Affinity purified rabbit anti-MEF2D (Cat. No. A303-521A Lot1, left image and Cat. No. A303-522A Lot1, right image) used at a dilution of 1:200 (1 µg/ml). *Detection:* DAB. *Counterstain:* Hematoxylin (blue).